The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys

Keyphrases

• Amphetamine 100%
• Acetylcholinesterase Inhibitors (AChEI) 100%
• Psychotic Experiences 100%
• Galantamine 100%
• Cebus Monkeys 100%
• Antipsychotics 57%
• Schizophrenic Patients 42%
• Acetylcholine Receptor (AChR) 28%
• Monotherapy 28%
• Extrapyramidal Side Effects 28%
• Muscarinic Receptor Agonists 28%
• Alzheimer's Disease 14%
• Cholinergic Receptors 14%
• Nicotinic Receptors 14%
• Clinical Trials 14%
• Clinical Application 14%
• Sedation 14%
• Antipsychotic Effect 14%
• Arousal 14%
• Acetylcholinesterase 14%
• Acetylcholine 14%
• Adjunctive Therapy 14%
• Alzheimer's Disease Patient 14%
• Unrest 14%
• Emesis 14%
• Antipsychotic Efficacy 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Haplorhini 100%
• Cholinesterase Inhibitor 100%
• Dexamphetamine 100%
• Cebus 100%
• Galantamine 100%
• Antipsychotic 85%
• Monotherapy 28%
• Alzheimer's Disease 28%
• Extrapyramidal Symptoms 28%
• Muscarinic Agent 28%
• Side Effect 14%
• Cholinergic Receptor 14%
• Nicotinic Receptor 14%
• Clinical Trial 14%
• Acetylcholine 14%
• Vomiting 14%
• Acetylcholinesterase 14%

Neuroscience

• Levoamphetamine 100%
• Behavior (Neuroscience) 100%
• Acetylcholinesterase Inhibitor 100%
• Galantamine 100%
• Antipsychotic 85%
• Alzheimer's Disease 28%
• Muscarinic Agonist 28%
• Extrapyramidal Symptoms 28%
• Cholinergic Receptor 14%
• Nicotinic Receptor 14%
• Acetylcholine 14%
• Acetylcholinesterase 14%
• Stereotypy 14%